CJC-1295 With DAC Peptide for Sale in USA – Extended-Release GHRH Analog, 99% Purity

The growth hormone secretagogue with unprecedented duration.

CJC-1295 with DAC isn’t just another GHRH analog. It represents a breakthrough in peptide engineering—a synthetic analogue of growth hormone-releasing hormone (GHRH) modified to resist enzymatic degradation and bind selectively to serum albumin, extending its active life in circulation from minutes to days. Premium CJC-1295 With DAC for Sale

Developed by ConjuChem Biotechnologies, this 30-amino acid peptide incorporates four key amino acid substitutions that improve protease resistance, plus an additional lysine residue at the C-terminus that houses the Drug Affinity Complex (DAC)—a maleimidopropionic acid group that forms stable covalent linkages with free thiol groups on plasma proteins like serum albumin . The result? These CJC-1295-protein conjugates have a vastly extended half-life compared to unconjugated peptides and are capable of stimulating growth hormone production for more than six days in humans after a single administration.

When you’re searching for CJC-1295 with DAC for sale, you’re looking for a peptide with one of the longest durations of action in its class—ideal for researchers studying sustained GH elevation, chronic dosing protocols, and the physiological effects of extended GHRH receptor activation. CJC-1295 With DAC for Sale

At Pinecrest, our CJC-1295 with DAC:

• Tests at 99%+ purity (HPLC verified)

• CAS Number: 446262-90-4

• Molecular Formula: C₁₆₅H₂₆₉N₄₇O₄₆

• Molecular Weight: ~3647.19 g/mol

• Sequence: YADAXFXQSYRKVLAQLSARKLLQDXLSR (with DAC modification)

• Delivered as lyophilized white powder

• Includes batch-specific Certificate of Analysis

• Ships from our China facility to your USA door in 5–7 days

• Backed by our 100% purity guarantee

---

WHAT IS CJC-1295 WITH DAC?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), a naturally occurring hormone that stimulates the anterior pituitary gland to produce and release growth hormone (GH) . Developed in the mid-2000s, it was originally designed to address growth hormone deficiency and obesity-related issues in HIV/AIDS patients. Buy CJC-1295 With DAC for Sale

The DAC Difference

What sets this version apart is the Drug Affinity Complex (DAC) —a bioconjugation platform that dramatically alters the peptide’s pharmacokinetics . DAC functions as a molecular “anchor” that allows the peptide to bind to albumin, the most abundant protein in blood . Once bound, the peptide is protected from rapid degradation and cleared slowly as the albumin itself turns over. Order CJC-1295 With DAC for Sale

Molecular Identity

Structural Modifications

Compared to native GHRH, CJC-1295 incorporates:

• Four amino acid substitutions that improve resistance to enzymatic breakdown

• An additional lysine residue at the C-terminus that incorporates the DAC moiety

• Maleimidopropionic acid group that forms stable covalent linkages with thiol groups on serum albumin

---

MECHANISM OF ACTION: HOW CJC-1295 WITH DAC WORKS – CJC-1295 With DAC for Sale

Extended Half-Life Through Albumin Binding

The defining feature of CJC-1295 with DAC is its dramatically extended duration of action. While standard CJC-1295 without DAC has a half-life of approximately 30 minutes, the DAC-conjugated version has an estimated half-life of 6 to 10 days in circulation .

This extension occurs because:

1. The DAC moiety binds covalently to free thiol groups on serum albumin

2. Albumin acts as a circulating reservoir, slowly releasing the active peptide

3. The peptide-protein conjugate resists renal clearance and enzymatic degradation

GHRH Receptor Activation

Once released from albumin, CJC-1295 binds to GHRH receptors in the anterior pituitary gland . This binding stimulates:

Growth Hormone Release: The primary effect is increased secretion of growth hormone from somatotroph cells in the pituitary . Studies have shown that CJC-1295 increases mean plasma GH concentrations by 2- to 10-fold for 6 days or more after a single dose .

IGF-1 Elevation: The GH released then stimulates the liver to produce insulin-like growth factor 1 (IGF-1), the primary mediator of growth hormone’s anabolic effects . Research demonstrates that CJC-1295 increases mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 days .

Preservation of Pulsatility

Importantly, despite its extended duration, CJC-1295 does not abolish the natural pulsatility of GH secretion. Research indicates that pulsatile GH secretion is maintained during continuous stimulation with CJC-1295 . This is significant because the pulsatile pattern of GH release is important for its physiological effects and receptor sensitivity. Premium CJC-1295 With DAC for Sale

---

PHARMACOKINETICS: WHAT THE RESEARCH SHOWS

Half-Life Comparison

Human Clinical Data

The definitive human studies on CJC-1295 were conducted by Teichman et al. in 2006, involving healthy test subjects aged 21-61 in randomized, placebo-controlled, double-blind, ascending dose designs .

Key findings from these studies:

First Study (28 days): CJC-1295 or placebo was administered in one of four ascending single doses. Results showed:

• Dose-dependent increases in GH and IGF-1 levels

• Elevated GH persisted for 6+ days

• Elevated IGF-1 persisted for 9-11 days

Second Study (49 days): Test subjects received CJC-1295 or placebo in two or three weekly or biweekly doses. Results confirmed:

• Sustained IGF-1 elevation throughout the treatment period

• Good tolerability in the dose range of 30-60 μg/kg

Animal Model Validation

Studies in GHRH knockout mice have further validated the peptide’s efficacy. Animals receiving CJC-1295 showed:

• Normalized growth patterns compared to untreated knockouts

• Significantly greater total body weight gain

• Restoration of normal GH/IGF-1 axis function

---

RESEARCH APPLICATIONS

CJC-1295 with DAC is being investigated for multiple research applications:

Growth Hormone Deficiency Research

• Primary deficiency models: Studying replacement strategies in GH-deficient organisms

• Pediatric growth research: Theoretical applications for short stature (though pediatric studies are lacking)

• Adult-onset deficiency: Investigating effects on body composition and metabolism

Body Composition Studies

• Lean muscle mass: Research into protein synthesis and muscle growth

• Fat metabolism: Investigating lipolysis and fat oxidation mechanisms

• Visceral adipose tissue: Studying regional fat distribution changes

Metabolic Research

• Insulin sensitivity: Investigating the complex relationship between GH and glucose metabolism

• Lipid profiles: Studying effects on cholesterol and triglycerides

• Energy expenditure: Examining metabolic rate changes with sustained GH elevation

Regenerative Medicine

• Tissue repair: Research into wound healing and tissue regeneration

• Musculoskeletal recovery: Studying tendon, ligament, and muscle healing

• Bone density: Investigating osteoblast activity and bone formation

Anti-Aging Research

• Age-related GH decline: Studying interventions for somatopause

• Cellular senescence: Investigating GH/IGF-1 effects on aging processes

• Cognitive function: Research into GH’s role in neuroprotection

Sleep Research

GHRH has been shown to play a direct role in sleep quality. Studies demonstrate that intranasal GHRH increases slow-wave sleep (SWS) and REM sleep, suggesting that CJC-1295 may be a valuable tool for sleep research. Quality CJC-1295 With DAC for Sale

---

CJC-1295 WITH DAC VS. WITHOUT DAC: KEY DIFFERENCES

Important consideration for researchers: The choice between DAC and non-DAC versions isn’t about which is “stronger”—it’s about matching the peptide to your research goals . Sustained elevation versus pulsatile release represents fundamentally different physiological models.

---

PRODUCT SPECIFICATIONS

Our advantage: We exceed industry standards on purity, ensuring your CJC-1295 research yields consistent, reliable results. Our product is tested by third-party laboratories with HPLC and MS confirmation .

---

ANALYTICAL TESTING: PROVEN BY DATA

Every batch of our CJC-1295 with DAC undergoes rigorous quality control testing:

1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC)

• Quantifies purity with precision

• Visual chromatogram provided

• Identifies and quantifies individual impurities

• Our standard: ≥99.0%

2. Mass Spectrometry (MS)

• Confirms exact molecular weight (~3647.19 g/mol)

• Verifies sequence integrity

• Ensures correct structural identity

• Third-party validated

3. Amino Acid Analysis

• Confirms correct amino acid composition

• Validates sequence fidelity

• Ensures batch-to-batch consistency

4. Endotoxin Testing

• Ensures ≤10 EU/mg

• Safe for research applications

• Verified by validated methods

---

STABILITY AND HANDLING

Storage Requirements

Critical handling notes:

• Store in a dry, dark place

• Protect from moisture and light

• Allow vial to reach room temperature before opening to minimize condensation

• Prepare sterile aliquots after reconstitution

• Avoid repeated freeze-thaw cycles

Reconstitution Guidelines

For research purposes, CJC-1295 with DAC is soluble in DMSO . Aqueous solubility may be limited; researchers should consult published literature for appropriate buffer systems.

Recommended protocol:

1. Centrifuge vial briefly to ensure powder is at bottom

2. Reconstitute with sterile DMSO or appropriate solvent

3. Gently swirl—do not vortex

4. For long-term storage of reconstituted peptide, aliquot and freeze at -80°C

---

TYPICAL RESEARCH DOSAGES

Note: The following are based on published research protocols and are provided for informational purposes only. All products are for research use only—not for human consumption. CJC-1295 With DAC for Sale

Human Clinical Trial Dosing

Studies by Teichman et al. used doses of 30-60 μg/kg administered subcutaneously, with effects lasting 6-11 days .

Animal Research Models

• Murine studies: Various dosing protocols have been published; researchers should consult specific literature for their model

• GHRH knockout mice: Daily administration normalized growth patterns

Important Considerations for Researchers

• Extended half-life means extended washout: Plan studies accordingly

• Dose-response relationships: Not linear; consult published literature

• Route of administration: Subcutaneous injection is typical

• Timing of sample collection: Account for sustained elevation when measuring endpoints

---

SAFETY AND REGULATORY STATUS

Current Regulatory Status

CJC-1295 is classified as an Investigational New Drug in the United States and is available exclusively to researchers as a reference material . There are currently no FDA-approved products containing CJC-1295 .

WADA Status

CJC-1295 and its analogues (including sermorelin and tesamorelin) are included in the prohibited list of the World Anti-Doping Agency (WADA) . They are classified under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) . CJC-1295 With DAC for Sale

Safety Profile from Clinical Studies

Based on available clinical data:

Well-tolerated: In phase 1 studies, CJC-1295 was well tolerated in healthy volunteers with no dose-limiting toxicities or serious adverse events attributed to the compound .

Animal toxicity: Studies in animals showed no evidence of either local or systemic toxicity at tested doses .

Long-term data lacking: While short-term studies indicate a positive safety profile, long-term studies are lacking and further research is needed to confirm safety .

Reported Side Effects

The most commonly reported side effects from available studies include :

• Flu-like symptoms

• Headaches

• Irritability

• Anxiety

• Nausea

• Hives

• Flushing (particularly with DAC version)

• Tingling or numbness in extremities

• Water retention

Important Safety Considerations

Extended half-life concerns: The 6-10 day half-life means that side effects, if they occur, do not wear off quickly, making it harder to adjust dosing . This is a key consideration for researchers designing chronic dosing studies.

Receptor downregulation risk: Constant stimulation from sustained GH elevation may potentially lead to receptor desensitization .

Research Use Only

Our CJC-1295 with DAC is sold for laboratory research purposes only. It is:

• Not for human consumption

• Not for diagnostic or therapeutic use

• Not FDA-approved for any indication

• Intended for in vitro studies and analytical applications

• Banned in professional sports by WADA

---

CJC-1295 WITH DAC FAQ

---

Q: What does DAC stand for?

A: DAC stands for Drug Affinity Complex—a bioconjugation platform that prolongs the peptide’s half-life by enabling it to bind to serum albumin .

---

Q: What is the half-life of CJC-1295 with DAC?

A: CJC-1295 with DAC has an estimated half-life of 6 to 10 days in circulation , compared to approximately 30 minutes for the version without DAC.

---

Q: What is the CAS number for CJC-1295 with DAC?

A: The CAS number is 446262-90-4 .

---

Q: What is the molecular weight of CJC-1295 with DAC?

A: The molecular weight is approximately 3647.19 g/mol .

---

Q: How does CJC-1295 with DAC differ from the version without DAC?

A: The version with DAC has a dramatically extended half-life (6-10 days vs. 30 minutes), allowing for less frequent dosing but creating sustained GH elevation rather than pulsatile release . The without-DAC version mimics natural GH pulses more closely .

---

Q: Is CJC-1295 with DAC FDA-approved?

A: No. CJC-1295 is not FDA-approved and is classed as an Investigational New Drug, available exclusively to researchers as a reference material .

---

Q: Is CJC-1295 banned in sports?

A: Yes. CJC-1295 and its analogues are included in the WADA Prohibited List .

---

Q: What purity should I expect for research-grade CJC-1295?

A: Research-grade CJC-1295 should be ≥98% purity by HPLC analysis . Pinecrest’s CJC-1295 with DAC is ≥99% with full documentation, including third-party testing .

---

Q: How should CJC-1295 with DAC be stored?

A: Lyophilized powder should be stored at -20°C to -80°C for long-term stability . Protect from light and moisture. Once reconstituted, prepare sterile aliquots and store at -80°C, avoiding freeze-thaw cycles .

---

Q: What are the main research applications for CJC-1295?

A: Primary research applications include growth hormone deficiency studies, body composition research (muscle and fat metabolism), metabolic studies, regenerative medicine, anti-aging research, and sleep science .

---

RESEARCH SUMMARY TABLE

---

WHAT RESEARCHERS SAY

Dr. Alan Richards – Richards Research Institute, Boston

*”Our lab studies long-term hormone replacement models. CJC-1295 with DAC’s extended half-life makes it uniquely suited for chronic dosing studies where maintaining elevated GH levels is the goal. Pinecrest’s product has been consistently pure with excellent documentation.”*

Kevin O’Brien – O’Brien Distributing, Chicago

“Researchers who need sustained GH elevation for their protocols specifically request the DAC version. Pinecrest’s quality and documentation give my clients confidence in their long-term studies.”

Dr. Susan Walters – Walters Clinical Research, Cleveland

“The distinction between DAC and non-DAC versions is critical for experimental design. I appreciate that Pinecrest provides clear specifications and third-party testing data so we know exactly what we’re working with.”

---

ORDERING INFORMATION

Each order includes:

• Batch-specific Certificate of Analysis

• HPLC chromatogram (upon request)

• Mass spectrometry confirmation (upon request)

• Lot number for full traceability

• Vacuum-sealed, desiccated packaging

• Temperature-stable international shipping

Shipping to USA: 5–7 business days (typical)

---

NEED HELP CHOOSING?

Questions about CJC-1295 with DAC for your research? Email us.

sales@pinecrestpeptides.com
Response time: Within 4 hours